1
|
Nunes C, Proença S, Ambrosini G, Pamies D, Thomas A, Kramer NI, Zurich MG. Integrating distribution kinetics and toxicodynamics to assess repeat dose neurotoxicity in vitro using human BrainSpheres: a case study on amiodarone. Front Pharmacol 2023; 14:1248882. [PMID: 37745076 PMCID: PMC10512064 DOI: 10.3389/fphar.2023.1248882] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 07/24/2023] [Indexed: 09/26/2023] Open
Abstract
For ethical, economical, and scientific reasons, animal experimentation, used to evaluate the potential neurotoxicity of chemicals before their release in the market, needs to be replaced by new approach methodologies. To illustrate the use of new approach methodologies, the human induced pluripotent stem cell-derived 3D model BrainSpheres was acutely (48 h) or repeatedly (7 days) exposed to amiodarone (0.625-15 µM), a lipophilic antiarrhythmic drug reported to have deleterious effects on the nervous system. Neurotoxicity was assessed using transcriptomics, the immunohistochemistry of cell type-specific markers, and real-time reverse transcription-polymerase chain reaction for various genes involved in the lipid metabolism. By integrating distribution kinetics modeling with neurotoxicity readouts, we show that the observed time- and concentration-dependent increase in the neurotoxic effects of amiodarone is driven by the cellular accumulation of amiodarone after repeated dosing. The development of a compartmental in vitro distribution kinetics model allowed us to predict the change in cell-associated concentrations in BrainSpheres with time and for different exposure scenarios. The results suggest that human cells are intrinsically more sensitive to amiodarone than rodent cells. Amiodarone-induced regulation of lipid metabolism genes was observed in brain cells for the first time. Astrocytes appeared to be the most sensitive human brain cell type in vitro. In conclusion, assessing readouts at different molecular levels after the repeat dosing of human induced pluripotent stem cell-derived BrainSpheres in combination with the compartmental modeling of in vitro kinetics provides a mechanistic means to assess neurotoxicity pathways and refine chemical safety assessment for humans.
Collapse
Affiliation(s)
- Carolina Nunes
- Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | - Susana Proença
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands
- Toxicology Division, Wageningen University, Wageningen, Netherlands
| | - Giovanna Ambrosini
- Bioinformatics Competence Center, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Bioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland
| | - David Pamies
- Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | - Aurélien Thomas
- Unit of Forensic Toxicology and Chemistry, CURML, Lausanne and Geneva University Hospitals, Geneva, Switzerland
- Faculty Unit of Toxicology, CURML, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Nynke I. Kramer
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands
- Toxicology Division, Wageningen University, Wageningen, Netherlands
| | - Marie-Gabrielle Zurich
- Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| |
Collapse
|
2
|
Achenbach P, Block F, Dafotakis M. Medikamentös-induzierte Polyneuropathien durch
Chemotherapeutika und Antiinfektiva. KLIN NEUROPHYSIOL 2022. [DOI: 10.1055/a-1869-3577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
Polyneuropathien können durch zahlreiche Wirkstoffe hervorgerufen oder
aggraviert werden. Insbesondere die Chemotherapeutika-induzierte Polyneuropathie
(CIPN) ist im Alltag von hoher Relevanz. Jedoch kann auch der Einsatz von
Antiinfektiva zu neuropathischen Beschwerden führen. Im Folgenden soll
ein Überblick über die wichtigsten mit Polyneuropathien
assoziierten Wirkstoffe der Substanzklassen sowie die klinischen Charakteristika
gegeben werden.
Collapse
|
3
|
Achenbach P, Block F, Dafotakis M. Grundlagen medikamentös-induzierter
Polyneuropathien. KLIN NEUROPHYSIOL 2022. [DOI: 10.1055/a-1886-2355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
ZusammenfassungZahlreiche Wirkstoffe können mit dem erstmaligen Auftreten oder dem
Fortschreiten neuropathischer Symptome in Verbindung gebracht werden.
Insbesondere im Kontext der modernen Polypharmazie kommt
medikamentös-induzierten Polyneuropathien eine besondere Bedeutung zu.
Die Schädigungsmechanismen und individuellen Risikofaktoren sind
vielfältig. In den meisten Fällen resultiert eine
längenabhängige, axonale Polyneuropathie mit vorwiegend
sensiblen Symptomen. Grundlegende Kenntnisse darüber, welche
Arzneimittel mit dem Auftreten einer Polyneuropathie assoziiert sind,
können dazu beitragen, das Auftreten dieser Nebenwirkung
frühzeitig zu erkennen. Die Verordnung entsprechender Medikamente sollte
vermieden werden, wenn das Risiko für den einzelnen Patienten als zu
hoch eingeschätzt wird. Unter Therapie sind regelmäßige
Kontrolluntersuchungen nötig, um bei neuauftretenden oder zunehmenden
Symptomen die Therapie so früh wie möglich anpassen oder
absetzen zu können. Die Prognose ist dann meist gut.
Collapse
Affiliation(s)
- Pascal Achenbach
- Neurologische Klinik, Universitätsklinik RWTH Aachen, Aachen,
Germany
| | - Frank Block
- Neurologische Klinik, Helios Klinik, Schwerin, Germany
| | - Manuel Dafotakis
- Neurologische Klinik, Universitätsklinik RWTH Aachen, Aachen,
Germany
| |
Collapse
|
4
|
McKenna MC, Marnane M, Sheane BJ, Connolly S. A case of multifocal motor neuropathy after initiation of ixekizumab for psoriatic arthopathy. Rheumatology (Oxford) 2021; 60:e282-e283. [PMID: 33629111 DOI: 10.1093/rheumatology/keab186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Mary Clare McKenna
- Clinical Neurophysiology Department, St Vincent's University Hospital, Santry, Dublin, Ireland
| | - Michael Marnane
- Neurology Department, Mater Misericordiae University Hospital, Santry, Dublin, Ireland
| | - Barry J Sheane
- Rheumatology Department, Sports Surgery Clinic, Santry, Dublin, Ireland
| | - Seán Connolly
- Clinical Neurophysiology Department, St Vincent's University Hospital, Santry, Dublin, Ireland
| |
Collapse
|